June 13, 2017 9:00am
AST is UP +$0.25 or +7.94% in the pre-market
SCiStar Phase 1/2a clinical trial shows three of six (50%) patients have now recovered two levels of motor function and previously-announced improvements in arm, hand and finger function at 3-months and 6-months following administration of AST-OPC1 have been confirmed and further increased at 9-months.
The new efficacy results show that previously reported meaningful improvements in arm, hand and finger function in the 10 million cell cohort treated with AST-OPC1 cells have been maintained and in some patients have been further enhanced even 9 months following dosing.
The Bottom Line: "Gains in motor function, such as the improvements observed in the SCiStar study to date, have been shown to increase a patient's ability to function independently following complete cervical spinal cord injuries.
AST had closed FLAT at $3.15